Hemab Therapeutics

hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. based in cambridge, massachusetts and copenhagen, denmark, hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. the company’s strategic guidance, hemab 1-2-5, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with high unmet need blood clotting disorders like glanzmann thrombasthenia, factor vii deficiency, bernard soulier syndrome, von willebrand disease and other serious disorders. learn more at hemab.com.